cyc 202 has been researched along with bms 387032 in 15 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (bms 387032) | Trials (bms 387032) | Recent Studies (post-2010) (bms 387032) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 76 | 3 | 56 |
| Protein | Taxonomy | cyc 202 (IC50) | bms 387032 (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.0103 | |
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.48 | |
| G1/S-specific cyclin-E2 | Homo sapiens (human) | 0.048 | |
| Vitamin K-dependent protein C | Homo sapiens (human) | 0.264 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.48 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.7538 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.48 | |
| Cyclin-A2 | Homo sapiens (human) | 0.0427 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.925 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.046 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0426 | |
| G1/S-specific cyclin-D2 | Homo sapiens (human) | 0.925 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.925 | |
| Cannabinoid receptor 2 | Mus musculus (house mouse) | 0.062 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.0772 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.1078 | |
| Cyclin-H | Homo sapiens (human) | 0.0823 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.1027 | |
| Cyclin-A1 | Homo sapiens (human) | 0.021 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.34 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.34 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.48 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP | 1 |
| Russu, WA; Shallal, HM | 1 |
| Baumli, S; Endicott, JA; Fischer, PM; Hole, AJ; Huang, S; Noble, ME; Pepper, C; Shao, H; Shi, S; Wang, S | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Akula, B; Athuluridivakar, S; Baker, SJ; Bharathi, EV; Billa, VK; Cosenza, SC; Mallireddigari, MR; Padgaonkar, A; Pallela, VR; Reddy, EP; Reddy, MV; Subbaiah, DR; Vasquez-Del Carpio, R | 1 |
| Joshi, G; Kalra, S; Kumar, R; Munshi, A | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Cui, S; Galons, H; Huang, Y; Ingarra, AM; Li, T; Lu, K; Oumata, N; Teng, Y; Yu, P; Zhang, Q; Zhao, L | 1 |
| Bian, J; Li, Z; Qin, Z; Tian, Y; Wang, J; Wu, T; Xu, C | 1 |
| Duan, Y; Han, J; Hou, S; Liao, C; Wang, Q; Xie, Z; Yang, X | 1 |
| Li, J; Liang, C; Liu, C; Qiang, T; Ren, X; Shi, Z; Tian, L; Xing, Y | 1 |
| Cress, WD; Freeman, SN; Ma, Y | 1 |
| Blagden, S; de Bono, J | 1 |
| Chen, R; Chubb, S; Fox, JA; Gandhi, V; Hawtin, RE; Keating, MJ; Plunkett, W; Wierda, WG | 1 |
| Giordano, A; Morales, F | 1 |
7 review(s) available for cyc 202 and bms 387032
| Article | Year |
|---|---|
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Topics: Amino Acid Sequence; Animals; Computer-Aided Design; Crystallography, X-Ray; Cyclin-Dependent Kinases; Drug Design; Humans; Models, Molecular; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Sequence Alignment | 2017 |
Recent advances in the development of cyclin-dependent kinase 7 inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase-Activating Kinase; Cyclin-Dependent Kinases; Drug Development; Humans; Protein Kinase Inhibitors; Pyrimidines; Triazines | 2019 |
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Cyclin-Dependent Kinase 9; Drug Development; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary | 2020 |
Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.
Topics: Antineoplastic Agents; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinases; Drug Discovery; Humans; Neoplasms; Protein Kinase Inhibitors | 2022 |
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Female; Humans; Pharmaceutical Preparations; Protein Kinase Inhibitors | 2022 |
Drugging cell cycle kinases in cancer therapy.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Binding Sites; Cyclin-Dependent Kinases; Flavonoids; Humans; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Roscovitine; Staurosporine; Sulfonamides; Thiazoles | 2005 |
Overview of CDK9 as a target in cancer research.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cyclic N-Oxides; Cyclin-Dependent Kinase 9; Flavonoids; Humans; Indolizines; Molecular Targeted Therapy; Neoplasms; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridinium Compounds; Roscovitine; Thiazoles; Urea | 2016 |
8 other study(ies) available for cyc 202 and bms 387032
| Article | Year |
|---|---|
A quantitative analysis of kinase inhibitor selectivity.
Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship | 2008 |
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity.
Topics: Cyclin-Dependent Kinase 9; Humans; Models, Molecular; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship | 2013 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Drug Screening Assays, Antitumor; Female; Heterografts; Humans; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasm Transplantation; Protein Kinases; Pyridines; Pyrimidines; Repressor Proteins; Structure-Activity Relationship | 2014 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
E2F4 deficiency promotes drug-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; E2F1 Transcription Factor; E2F4 Transcription Factor; Fibroblasts; Flavonoids; Humans; Lung Neoplasms; Mice; Mice, Knockout; Oxazoles; Piperidines; Protein Kinase Inhibitors; Purines; RNA, Small Interfering; Roscovitine; Thiazoles; Transcription Factors; Tumor Cells, Cultured | 2004 |
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Caspases; Cyclin-Dependent Kinases; Female; Flavonoids; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Membrane Potential, Mitochondrial; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Oxazoles; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; RNA Polymerase II; RNA, Neoplasm; Roscovitine; Thiazoles; Transcription, Genetic; X-Linked Inhibitor of Apoptosis Protein | 2009 |